<DOC>
	<DOCNO>NCT00440479</DOCNO>
	<brief_summary>The primary aim observational study collect safety effectiveness data bortezomib use first relapse group multiple myeloma patient receive specific well define first line treatment within previous clinical study .</brief_summary>
	<brief_title>ADVANCE : An Observational Study To Determine Bortezomib Safety Effectiveness First Relapse After Participation In First Line HOVON-49/50 Clinical Studies .</brief_title>
	<detailed_description>There need physician evaluate result bortezomib treatment homogenous patient population regard multiple myeloma treatment first line . For reason current study , ADVANCE , design structurally collect data daily practice use bortezomib treatment first relapse patient specific well define first line treatment ( i.e . patient participate HOVON-49 HOVON-50 study ) . In HOVON study patient randomize either receive thalidomide , part first line treatment . Therefore , effect pre-treatment thalidomide duration , effectiveness safety bortezomib treatment first relapse study specifically . The analysis particular type data , however , descriptive . All adverse event , regardless seriousness , severity , presume relationship bortezomib therapy record case report form , i.e. , form patient study need data record , report sponsor within current timeline . The sponsor assume responsibility appropriate reporting adverse event regulatory authority . This project 'post authorization study ( PAS ) ' . This mean routinely available medical data collect , patient ' permission , additional intervention diagnostic procedure do specifically study . Because study observational , dosage , administration duration treatment discretion treat physician</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients sign statement agree collection clinical data project patient first relapse progressive disease treatment HOVON49 HOVON50 study treat bortezomib . Prior enrollment HOVON54 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>hematological neoplasm</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>bortezomib</keyword>
	<keyword>proteasome inhibitor</keyword>
</DOC>